上皮性卵巢癌(EOC)是女性中第八大最常见的癌症，大多数患者被诊断为晚期，尽管对一线治疗（通常是细胞减灭术联合铂类化疗）的初始反应很高，但晚期卵巢癌患者的总体5年生存率仍然很低，仅为29%3。pattern_str[23]

pattern_str[26]Epithelial ovarian cancer (EOC) is the eighth most common cancer in women. Most patients are diagnosed with advanced ovarian cancer. Despite a high initial response to first-line therapy, usually cytolytic therapy combined with platinum-based chemotherapy, the overall 5-year survival rate for patients with advanced ovarian cancer remains low at 29%3.pattern_str[23]

pattern_str[26] pattern_str[33]pattern_str[23]

pattern_str[39]芦卡帕尼pattern_str[23]

pattern_str[45] pattern_str[23]

　　pattern_str[26]Rucaparibpattern_str[57]芦卡帕尼（以前称为pattern_str[26]CO-338pattern_str[65]、pattern_str[26]AG-014447pattern_str[57]和pattern_str[26]PF-01367338pattern_str[57]）是一种设计合理、口服给药的pattern_str[26]PARP1pattern_str[65]、pattern_str[26]PARP2pattern_str[65]和pattern_str[26]PARP3pattern_str[65]小分子抑制剂。芦卡帕尼的推荐剂量和时间表是pattern_str[26]600pattern_str[65]毫克（两片pattern_str[26]300pattern_str[65]毫克片剂），每天口服两次pattern_str[26](BID)pattern_str[65]。pattern_str[23]

pattern_str[26] pattern_str[23]

pattern_str[57]　　不过芦卡帕尼可以根据患者的实际情况进行给药治疗，芦卡帕尼现在也已经在印度成功上市，在印度代购有详细药品介绍。pattern_str[23]

pattern_str[26]However, rucapanil can be administered according to the actual situation of the patient. Rucapanil has been successfully marketed in India, and there is a detailed introduction of the drug in India.pattern_str[23]

pattern_str[152]pattern_str[23]